Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Factors affecting inter-individual variability in endoxifen concentrations in patients with breast cancer: results from the prospective TOTAM trial.

Breast cancer research and treatment - 1 Aug 2022

Braal C Louwrens, Westenberg Justin D, Buijs Sanne M, Abrams Steven, Mulder Tessa A M, van Schaik Ron H N, Koolen Stijn L W, Jager Agnes, Mathijssen Ron H J

Abstract excerpt

INTRODUCTION: Endoxifen-the principal metabolite of tamoxifen-is subject to a high inter-individual variability in serum concentration. Numerous attempts have been made to explain this, but thus far only with limited success. By applying predictive modeling, we aimed to identify factors that determine the inter-individual variability. Our purpose was to develop a prediction model for endoxifen concentrations, as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Genotype

Share to Tamoxifen

Source

Open in PubMed Open full text

Identifiers

PMID: 35842520
DOI: 10.1007/s10549-022-06643-y
PMCID: PMC9338137

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Factors affecting inter-individual variability in endoxifen concentrations in patients with breast cancer: results from the prospective TOTAM trial.PMID 35842520Read ↗

Factors Affecting Inter-individual Variability in Endoxifen Concentrations in Patients: Results From the Prospective TOTAM TrialSemantic proximity Read ↗

Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.Semantic proximity Read ↗

Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast CancerSemantic proximity Read ↗

Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifenSemantic proximity Read ↗

Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment.Semantic proximity Read ↗

Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scale.Semantic proximity Read ↗

Model‐Based Quantification of Impact of Genetic Polymorphisms and Co‐Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast CancerSemantic proximity Read ↗

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of TamoxifenSemantic proximity Read ↗

CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy.Semantic proximity Read ↗

Population pharmacokinetic modeling of tamoxifen and its active metabolite endoxifen in healthy volunteers of African ancestry genotyped for CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP3A5.Semantic proximity Read ↗

Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with TamoxifenSemantic proximity Read ↗

Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.